TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 25-OH Vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Change of the Reflective Total Nasal Symptoms Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with standard plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of abstinence from tobacco use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Point prevalence of tobacco use cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with persisting peri-implantitis following peri-implant surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with persisting peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of implants with persisting peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of implants with persisting peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Complete remission (CR) + complete remission incomplete (CRi) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of p-cresol sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived ease of priming
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in empiric antimicrobial use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adjusted Mean 24-h Systolic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients without treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PD-L1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T-cell Bim expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers in urine and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Emerging Behaviors Scale (EBS) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reliable Change Index on ADHD Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hemoglobin A1C (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of Screening Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tendon Retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute Kidney Injury stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Return of function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UTI symptom resolution rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new ischemic stroke, systemic embolism, and cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Final Clinical Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of white blood cell count (WBCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in HbA1c%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All-cause rebleeding
Endpoint domain: Mortality/survival
Primary endpoint: Persistence and duration of ZIKV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Emax of CKD-519 CETP Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 of CKD-519 CETP Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anastomosis-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Excess Weight Loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of BIB Treated Participants With Significantly Greater Weight Loss Than the Control Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune response measured by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response measured by transcriptomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lactic acid value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative decrease in N-terminal prohormone B-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Office hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Running related injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of associated autoimmune diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical characteristics of NCWS and IBS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of colonization sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to new evidence based practices
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Right and left ventricular volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee Pain: Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Objective Tumour Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of requests for Oncotype DX testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: International index of erectile dysfunction (IIEF)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Absorption of oral docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute improvement in cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until revision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Micrographia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported problem with handwriting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Writing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Categorized as Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of high dose kaletra in HIV treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of high dose kaletra in HIV treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Volume of Striae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Stretch Mark Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: progression free survival probability at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: final postoperative uncorrected visual acuity (UCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final postoperative best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate blood value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: base deficit blood value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pH blood value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability of the PP-MI Exercises: Utility Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the PP-MI Exercises: Ease Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discontinuation rate associated with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of days of self-reported cannabis use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cervical muscle powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Truncal muscle powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shoulder girdle muscle powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip girdle muscle powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: kinesthetic ability trainer static score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kinesthetic ability trainer static dynamic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity specific balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of NK Cells (CD3-/CD56+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of Gamma Delta T Cells (CD4-CD8-)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of Gamma T cell subsets (CD3+/CD4/CD8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in plasma unconjugated bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in fecal fat excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: increase in fecal bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients with Constant Intraocular Pressure <18 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Frequency of wearing orthodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with positive skin patch test reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain on day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurable Gastrin-17 Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a hemodynamic abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Experienced Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal Residual Disease (MRD) Negativity Rate in Bone Marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Meibomium Gland Dropout Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Sensitivity Index (ASI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants with Adverse Events (AEs) and Treatment Emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-management of heart failure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PrEP Linkage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mania severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL-c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Observed Parenting Effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Worsening of renal function by at least KDIGO grade 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Troponin greater than 99th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visuospatial Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Resting tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Exercise Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of Exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported Psychological Impact of Exercises
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of subjects achieving safe GH and normal IGF-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Monocular Mesopic Contrast Sensitivity Without Glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wexner fecal incontinence severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: St. Mark's fecal incontinence severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain self-rating scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mood self-rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress self-rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of increased immune population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of decreased immune population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of statically different phenotypes compared to control patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Middle Meatal Synechiae
Endpoint domain: Adverse events/effects
Primary endpoint: Response to Bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation of retinal vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tinnitus Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of grade 3 or greater immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Psychotic, manic, aggressive, and depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of intubation condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Test Scores for Facial Emotion Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA Level Below 50 Copies/mL at Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of methadone in treating chronic neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Death-Censored Graft Failure
Endpoint domain: Mortality/survival
Primary endpoint: changes in plasma insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best Cosmetic Appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Hemoglobin at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With an at Least 1gm/dL Increase in Hgb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With an at Least 2gm/dL Increase in Hgb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of VB6-845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and tolerability of VB6-845
Endpoint domain: Adverse events/effects
Primary endpoint: Extent and severity of adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in recall of Word List
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in recall of Name-Face pairs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Interleukin-8 (IL-8) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Basal body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maternal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in electrical activity of the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: evolution of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evolution of knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance levels of messenger RNA transcriptome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in abundance of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes from baseline in the resting flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use with non main partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with any Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Global self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects with RA participating in CE interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lund-Kennedy Endoscopy Score (LKES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque-Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fMRI BOLD responses to Stop Signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI BOLD responses in Go-NoGo CPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Methylation Index (MI) of the 11p15 region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Terminal phase cancer ratio
Endpoint domain: Mortality/survival
Primary endpoint: Change in musculoskeletal resiliency as measured by physical activity (step counts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in musculoskeletal resiliency as measured by Lower Extremity Physical Activities of Daily Living (LE PADLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in musculoskeletal resiliency as measured by PROMIS Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in musculoskeletal resiliency as measured by PROMIS Pain Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive resiliency as measured by 3D-CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in heart variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of MDX-010
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of MDX-010
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes